Vaginal Bifidobacterium breve for preventing urogenital infections: Development of delayed release mucoadhesive oral tablets
| Autor: | Carola Eleonora Parolin, Teresa Cerchiara, Beatrice Vitali, Luz María Melgoza, Francesco Dalena, Barbara Luppi, Federica Bigucci, Claudio Foschi, Antonella Marangoni, Barbara Giordani, Angela Abruzzo |
|---|---|
| Přispěvatelé: | Giordani, Barbara, Melgoza, Luz Maria, Parolin, Carola, Foschi, Claudio, Marangoni, Antonella, Abruzzo, Angela, Dalena, Francesco, Cerchiara, Teresa, Bigucci, Federica, Luppi, Barbara, Vitali, Beatrice |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Delayed release ved/biology.organism_classification_rank.species Pharmaceutical Science Administration Oral Bifidobacterium breve BC204 02 engineering and technology Bifidobacterium breve HeLa Cell Intestinal mucosa Oral administration Urogenital infection Delayed-Action Preparation Intestinal Mucosa Caco-2 Cell Candidiasis Adhesiveness Bacterial Infections 021001 nanoscience & nanotechnology Antimicrobial Adhesivene medicine.anatomical_structure Vagina Candidiasi Female Urogenital Disease Female 0210 nano-technology Tablets Human 030106 microbiology Mucoadhesion Bacterial Infection Microbiology 03 medical and health sciences medicine Humans Microencapsulation ved/biology Genitourinary system business.industry Female Urogenital Diseases Caco-2 Delayed-Action Preparations Caco-2 Cells business Tablet HeLa Cells |
| Popis: | Bifidobacteria are predominant microorganisms in the intestinal flora, but at the same time represent a subdominant group of the vaginal microbiota. For this reason, oral administration of these probiotic bacteria can provide beneficial effect for both intestinal and urogenital ecosystems. The first aim of this study was to test the strain Bifidobacterium breve BC204, isolated from a vaginal swab of a healthy woman, for its capability to adhere to human cells, to survive to gastric acids and bile salts and to exert antimicrobial activities. The second aim of the work was to develop an oral formulation able to guarantee bacterial survival during storage and administration, thus favouring intestinal and vaginal colonization. B. breve BC204 was encapsulated by spray-drying and subsequently formulated in time-dependent erodible tablets. B. breve BC204 showed good ability to adhere to Caco-2 cells and moderate ability to resist to gastrointestinal stress. Moreover, it exerted a strong antimicrobial activity against urogenital and enteric pathogens. Microencapsulation followed by tablet production allowed high loading and survival of B. breve BC204, associated to a delayed release and mucoadhesive ability. These characteristics are required to achieve appropriate amount and persistence of viable microbial cells in the treatment site. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|